Premium
Late‐onset P neumocystis jirovecii pneumonia in solid organ transplant recipients
Author(s) -
PerezOrdoño L.,
Hoyo I.,
Sanclemente G.,
Ricart M.J.,
Cofan F.,
PerezVilla F.,
Bellacasa J. Puig,
Moreno A.,
Cervera C.
Publication year - 2014
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12184
Subject(s) - medicine , rituximab , pneumocystis jirovecii , organ transplantation , pneumonia , solid organ , pneumocystis pneumonia , transplantation , immunology , gastroenterology , antibody
Anti‐ P neumocystis prophylaxis is recommended for at least 6–12 months after solid organ transplantation, as most cases of P neumocystis jirovecii pneumonia ( PCP ) occur during the first year post transplantation. Herein, we report 4 cases of late‐onset PCP (>1 year post transplant). PCP appeared in a range of 50–68 months post transplant. Two cases had history of humoral rejection episodes treated with rituximab, and the other 2 had low CD 4+ T‐cell count (<200 cells/mm 3 ) at the time of diagnosis. All 4 patients survived. In conclusion, although the number of cases is low, we must be aware of the possibility of late‐onset PCP in solid organ transplant patients. The role of previous use of rituximab or persistent CD 4+ T‐cell lymphopenia should be addressed in future studies.